Literature DB >> 2545499

Antipyrine clearance per unit liver volume in cirrhotics with and without hepatocellular carcinoma indicating a correlation with histological change of the liver.

S Noda1, S Kawata, S Miyoshi, Y Minami, S Tarui.   

Abstract

The antipyrine metabolizing capacity was studied in 12 patients with cirrhosis of the liver and 12 with cirrhosis and hepatocellular carcinoma (HCC). Antipyrine clearance (Cl) and liver volume (LV) were measured and the antipyrine clearance per unit liver volume (Cl/LV) was calculated. The patients with HCC showed a significantly lower Cl value than those without HCC but there was no significant difference in Cl/LV between the two groups. This suggested that the lower Cl values in the HCC patients resulted from a decrease in residual liver mass. Cl/LV showed positive correlation with % parenchymal cell mass as an indicator of residual parenchymal cell mass per unit volume of liver. This result showed a correlation of Cl/LV with histological change of the liver in cirrhotics.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545499     DOI: 10.1007/BF02774191

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  23 in total

1.  The estimation of antipyrine in biological materials.

Authors:  B B BRODIE; J AXELROD
Journal:  J Biol Chem       Date:  1949-05       Impact factor: 5.157

2.  Portal venous hemodynamics in hepatocellular carcinoma. Effects of hepatic artery embolization.

Authors:  K Ohnishi; S Sato; T Tsunoda; S Sugita; F Nomura; S Iida
Journal:  Gastroenterology       Date:  1987-09       Impact factor: 22.682

3.  Computed tomography assisted volumetric analysis of primary liver tumor as a measure of response to therapy.

Authors:  D S Ettinger; P K Leichner; S S Siegelman; E K Fishman; J L Klein; S E Order
Journal:  Am J Clin Oncol       Date:  1985-10       Impact factor: 2.339

4.  Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography.

Authors:  S B Heymsfield; T Fulenwider; B Nordlinger; R Barlow; P Sones; M Kutner
Journal:  Ann Intern Med       Date:  1979-02       Impact factor: 25.391

Review 5.  Dynamic interactions among host factors that influence antipyrine metabolism: implications for the design and interpretation of studies on ethnic pharmacokinetic variations.

Authors:  E S Vesell
Journal:  Prog Clin Biol Res       Date:  1986

6.  Drugs as indicators of hepatic function.

Authors:  R A Branch
Journal:  Hepatology       Date:  1982 Jan-Feb       Impact factor: 17.425

7.  The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.

Authors:  C J Roberts; L Jackson; M Halliwell; R A Branch
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

8.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059

9.  Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.

Authors:  R A Branch; D G Shand; G R Wilkinson; A S Nies
Journal:  J Clin Invest       Date:  1974-04       Impact factor: 14.808

10.  Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism.

Authors:  G C Farrell; W G Cooksley; P Hart; L W Powell
Journal:  Gastroenterology       Date:  1978-10       Impact factor: 22.682

View more
  3 in total

Review 1.  Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.

Authors:  J V St Peter; W M Awni
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

2.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 3.  Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.

Authors:  D J Morgan; A J McLean
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.